Newsroom

July 2015

• Press release Jul 27, 2015

  Novartis Foundation confirms new members of its Board of trustees, including new Chairman Dr. Joerg Reinhardt

  Dr. Joerg Reinhardt, Chairman of the Novartis Board of Directors, will serve as Chairman of the Foundation Board of trustees New trustees also include Professor Peter Piot of the London School…
• Press release Jul 24, 2015

  FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer

  Approval is based on pivotal Phase II study in which objective response rate (ORR) in patients with laBCC was 58%; responses were durable[1] Basal cell carcinoma, the most common form of skin…
• Press release Jul 24, 2015

  Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones

  CHMP positive opinion for EU approval of Tafinlar and Mekinist combination in BRAF V600 mutation-positive melanoma, the most aggressive type of skin cancer  FDA grants priority review for…
• Press release Jul 24, 2015

  Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder

  If approved, Revolade would be the first treatment option in its class in the EU for certain patients with SAA  Approximately 40% of SAA patients unresponsive to initial immunosuppressive…
• 
  Story Jul 22, 2015 From Our Labs

  Five things to look for in a scientific mentor

• Press release Jul 21, 2015

  Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches

  Sales, core[1] operating income and core EPS grew (cc[1]) for continuing operations[2] in Q2: Net sales amounted to USD 12.7 billion (-5%, +6% cc) Operating income was USD 2.3…
• Press release Jul 21, 2015

  Novartis: solide performance au deuxième trimestre grâce à la force de l'innovation et aux progrès des nouveaux lancements

  Croissance des ventes, du résultat opérationnel core[1] et du BPA core (tcc[1]) des activités poursuivies[2] au T2: Le chiffre d'affaires net s'est élevé à USD 12,7 milliards (-5%, +6% tcc). Le…
• Press release Jul 21, 2015

  Novartis erzielt im zweiten Quartal eine solide Performance mit starken Innovationen und Fortschritten bei Neueinführungen

  Die fortzuführenden Geschäftsbereiche[2] steigern im zweiten Quartal den Umsatz, das operative Kernergebnis[1] und den Kerngewinn pro Aktie (kWk[1]): Der Nettoumsatz beläuft sich auf USD 12,7…
• Press release Jul 16, 2015

  Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients

  WHO prequalified Coartem® 80/480mg is the first and only  high strength malaria treatment available for donor-funded public sector procurement  Coartem® 80/480mg reduces the pill burden for…
• 
  Story Jul 14, 2015 From Our Labs

  How I built a mini-gut with next to no biology training

• 
  Story Jul 13, 2015 Discovery

  Rewriting the playbook for clinical testing in a rare disease

  A Novartis team blazes new trails with an experimental treatment for spinal muscular atrophy.

• Press release Jul 07, 2015

  Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization

  First in the world approval brings hope of longer life and fewer hospitalizations for millions of Americans with heart failure with reduced ejection fraction Entresto is the first and only treatment…